Literature DB >> 28800711

Getting Better or Getting Well? The Patient Acceptable Symptom State (PASS) Better Predicts Patient's Satisfaction than the Decrease of Pain, in Knee Osteoarthritis Subjects Treated with Viscosupplementation.

Thierry Conrozier1, Matthieu Monet1, Anne Lohse1, Raghu Raman2.   

Abstract

Background In the management of knee osteoarthritis (OA), patient-reported-outcomes (PROs) are being developed for relevant assessment of pain. The patient acceptable symptom state (PASS) is a relevant cutoff, which allows classifying patients as being in "an acceptable state" or not. Viscosupplementation is a therapeutic modality widely used in patients with knee OA that many patients are satisfied with despite meta-analyses give conflicting results. Objectives To compare, 6 months after knee viscosupplementation, the percentage of patients who reached the PASS threshold (PASS +) with that obtained from other PROs. Methods Data of 53 consecutive patients treated with viscosupplementation (HANOX-M-XL) and followed using a standardized procedure, were analyzed at baseline and month 6. The PROs were Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and function, patient's global assessment of pain (PGAP), patient's self-assessment of satisfaction, PASS for WOMAC pain and PGAP. Results At baseline, WOMAC pain and PGAP (range 0-10) were 4.6 (1.1) and 6.0 (1.1). At month 6, they were 1.9 (1.2) and 3.1 (5) ( P < 0.0001). At 6 months, 83% of patients were "PASS + pain," 100% "PASS + function," 79% "PASS + PGAP," 79% were satisfied, and 73.6% experienced a ≥50% decrease in WOMAC pain. Among "PASS + pain" and "PASS + PGAP" subjects, 90% and 83.3% were satisfied with the treatment, respectively. Conclusion In daily practice, clinical response to viscosupplementation slightly varies according to PROs. "PASS + PGAP" was the most related to patient satisfaction.

Entities:  

Keywords:  PASS; WOMAC; hyaluronic acid; intra-articular injection; knee osteoarthritis; patient-reported outcome; viscosupplementation

Mesh:

Substances:

Year:  2017        PMID: 28800711      PMCID: PMC6139588          DOI: 10.1177/1947603517723072

Source DB:  PubMed          Journal:  Cartilage        ISSN: 1947-6035            Impact factor:   4.634


  43 in total

Review 1.  EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT).

Authors:  K M Jordan; N K Arden; M Doherty; B Bannwarth; J W J Bijlsma; P Dieppe; K Gunther; H Hauselmann; G Herrero-Beaumont; P Kaklamanis; S Lohmander; B Leeb; M Lequesne; B Mazieres; E Martin-Mola; K Pavelka; A Pendleton; L Punzi; U Serni; B Swoboda; G Verbruggen; I Zimmerman-Gorska; M Dougados
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

Review 2.  Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria.

Authors:  Thao Pham; Désirée Van Der Heijde; Marissa Lassere; Roy D Altman; Jennifer J Anderson; Nicholas Bellamy; Marc Hochberg; Lee Simon; Vibeke Strand; Thasia Woodworth; Maxime Dougados
Journal:  J Rheumatol       Date:  2003-07       Impact factor: 4.666

3.  Radiological assessment of osteo-arthrosis.

Authors:  J H KELLGREN; J S LAWRENCE
Journal:  Ann Rheum Dis       Date:  1957-12       Impact factor: 19.103

Review 4.  Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition.

Authors:  David S Jevsevar
Journal:  J Am Acad Orthop Surg       Date:  2013-09       Impact factor: 3.020

5.  Development of multinational definitions of minimal clinically important improvement and patient acceptable symptomatic state in osteoarthritis.

Authors:  Nicholas Bellamy; Marc Hochberg; Florence Tubach; Emilio Martin-Mola; Hassane Awada; Claire Bombardier; Najia Hajjaj-Hassouni; Isabelle Logeart; Marco Matucci-Cerinic; Mart van de Laar; Désirée van der Heijde; Maxime Dougados
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-07       Impact factor: 4.794

Review 6.  The discrepancy between recommendations and clinical practice for viscosupplementation in osteoarthritis: mind the gap!

Authors:  A Migliore; E Bizzi; J Herrero-Beaumont; R J Petrella; R Raman; X Chevalier
Journal:  Eur Rev Med Pharmacol Sci       Date:  2015-04       Impact factor: 3.507

7.  OARSI guidelines for the non-surgical management of knee osteoarthritis.

Authors:  T E McAlindon; R R Bannuru; M C Sullivan; N K Arden; F Berenbaum; S M Bierma-Zeinstra; G A Hawker; Y Henrotin; D J Hunter; H Kawaguchi; K Kwoh; S Lohmander; F Rannou; E M Roos; M Underwood
Journal:  Osteoarthritis Cartilage       Date:  2014-01-24       Impact factor: 6.576

8.  "Feeling better" or "feeling well" in usual care of hip and knee osteoarthritis pain: determination of cutoff points for patient acceptable symptom state (PASS) and minimal clinically important improvement (MCII) at rest and on movement in a national multicenter cohort study of 2414 patients with painful osteoarthritis.

Authors:  Serge Perrot; Philippe Bertin
Journal:  Pain       Date:  2012-10-30       Impact factor: 6.961

9.  A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project.

Authors:  F Navarro-Sarabia; P Coronel; E Collantes; F J Navarro; A Rodriguez de la Serna; A Naranjo; M Gimeno; G Herrero-Beaumont
Journal:  Ann Rheum Dis       Date:  2011-08-17       Impact factor: 19.103

Review 10.  Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice.

Authors:  Cyrus Cooper; François Rannou; Pascal Richette; Olivier Bruyère; Nasser Al-Daghri; Roy D Altman; Maria Luisa Brandi; Sabine Collaud Basset; Gabriel Herrero-Beaumont; Alberto Migliore; Karel Pavelka; Daniel Uebelhart; Jean-Yves Reginster
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-08-08       Impact factor: 4.794

View more
  9 in total

1.  EUROVISCO Recommendations for Optimizing the Clinical Results of Viscosupplementation in Osteoarthritis.

Authors:  Thierry Conrozier; Jordi Monfort; Xavier Chevalier; Raghu Raman; Pascal Richette; Demirhan Diraçoglù; Hervé Bard; Dominique Baron; Jörg Jerosch; Alberto Migliore; Yves Henrotin
Journal:  Cartilage       Date:  2018-06-21       Impact factor: 4.634

2.  Knee Osteoarthritis Pain Management with an Innovative High and Low Molecular Weight Hyaluronic Acid Formulation (HA-HL): A Randomized Clinical Trial.

Authors:  Alberto Migliore; Tomasz Blicharski; Rafal Plebanski; Zbigniew Zegota; Győrfi Gyula; François Rannou; Jean-Yves Reginster
Journal:  Rheumatol Ther       Date:  2021-08-30

3.  Safety and Predictive Factors of Short-Term Efficacy of a Single Injection of Mannitol-Modified Cross-Linked Hyaluronic Acid in Patients with Trapeziometacarpal Osteoarthritis. Results of a Multicentre Prospective Open-Label Pilot Study (INSTINCT Trial).

Authors:  Jérémy Dauvissat; Christophe Rizzo; Henri Lellouche; Jérôme Porterie; Sylvie Melac-Ducamp; Vincent Locquet; Vincent Travers; Bernard Maillet; Thierry Conrozier
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2018-06-21

4.  Impact of obesity, structural severity and their combination on the efficacy of viscosupplementation in patients with knee osteoarthritis.

Authors:  Thierry Conrozier; Florent Eymard; Mickael Chouk; Xavier Chevalier
Journal:  BMC Musculoskelet Disord       Date:  2019-08-17       Impact factor: 2.362

5.  Commentary: New Viscoelastic Hydrogel Hymovis MORE Single Intra-Articular Injection for the Treatment of Knee Osteoarthritis in Sportsmen: Safety and Efficacy Study Results.

Authors:  Thierry Conrozier; Thomas Lohse
Journal:  Front Pharmacol       Date:  2021-12-22       Impact factor: 5.810

6.  Effectiveness and cost-effectiveness of a combined lifestyle intervention compared with usual care for patients with early-stage knee osteoarthritis who are overweight (LITE): protocol for a randomised controlled trial.

Authors:  Nuria E J Jansen; Dieuwke Schiphof; Edwin Oei; Judith Bosmans; Jolande van Teeffelen; Anita Feleus; Jos Runhaar; Joyce van Meurs; Sita M A Bierma-Zeinstra; Marienke van Middelkoop
Journal:  BMJ Open       Date:  2022-03-04       Impact factor: 2.692

7.  Open-Label Pilot Study of a Single Intra-Articular Injection of Mannitol-Modified Cross-Linked Hyaluronic Acid (HANOX-M-XL) for the Treatment of the First Metatarsophalangeal Osteoarthritis (Hallux Rigidus): The REPAR Trial.

Authors:  Laurent Galois; Jean-Yves Coillard; Jérôme Porterie; Sylvie Melac-Ducamp; Thierry Conrozier
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2022-03-10

Review 8.  A Review of the Clinical Effectiveness and Safety of Hybrid Cooperative Complexes in Intra-articular Viscosupplementation.

Authors:  Marcin Domżalski; Alberto Migliore
Journal:  Rheumatol Ther       Date:  2022-05-03

9.  Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements.

Authors:  Alberto Migliore; Gianfranco Gigliucci; Liudmila Alekseeva; Sachin Avasthi; Raveendhara R Bannuru; Xavier Chevalier; Thierry Conrozier; Sergio Crimaldi; Nemanja Damjanov; Gustavo Constantino de Campos; Demirhan Diracoglu; Gabriel Herrero-Beaumont; Giovanni Iolascon; Ruxandra Ionescu; Natasa Isailovic; Jörg Jerosch; Jorge Lains; Emmanuel Maheu; Souzi Makri; Natalia Martusevich; Marco Matucci Cerinc; Mihaela Micu; Karel Pavelka; Robert J Petrella; Umberto Tarantino; Raghu Raman
Journal:  Ther Adv Musculoskelet Dis       Date:  2019-12-19       Impact factor: 5.346

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.